Recombinant multi-species TMEM237 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TMEM237 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a tetraspanin protein that is thought to be involved in WNT signaling. Defects in this gene are a cause of Joubert syndrome-14. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
The Alternative Names of target: TMEM237,Transmembrane protein 237,Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 4 protein,JBTS14,ALS2CR4

Target products collectionGo to TMEM237 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP2067-Ab-1/ GM-Tg-hg-IP2067-Ab-2 Human TMEM237 protein Human
GM-Tg-rg-IP2067-Ab-1/ GM-Tg-rg-IP2067-Ab-2 Rat TMEM237 protein Rat
GM-Tg-mg-IP2067-Ab-1/ GM-Tg-mg-IP2067-Ab-2 Mouse TMEM237 protein Mouse
GM-Tg-cynog-IP2067-Ab-1/ GM-Tg-cynog-IP2067-Ab-2 Cynomolgus/Rhesus macaque TMEM237 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP2067-Ab-1/ GM-Tg-felg-IP2067-Ab-2 Feline TMEM237 protein Feline
GM-Tg-cang-IP2067-Ab-1/ GM-Tg-cang-IP2067-Ab-2 Canine TMEM237 protein Canine
GM-Tg-bovg-IP2067-Ab-1/ GM-Tg-bovg-IP2067-Ab-2 Bovine TMEM237 protein Bovine
GM-Tg-equg-IP2067-Ab-1/ GM-Tg-equg-IP2067-Ab-2 Equine TMEM237 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP2067-Ab-1/ GM-Tg-hg-IP2067-Ab-2; GM-Tg-rg-IP2067-Ab-1/ GM-Tg-rg-IP2067-Ab-2;
GM-Tg-mg-IP2067-Ab-1/ GM-Tg-mg-IP2067-Ab-2; GM-Tg-cynog-IP2067-Ab-1/ GM-Tg-cynog-IP2067-Ab-2;
GM-Tg-felg-IP2067-Ab-1/ GM-Tg-felg-IP2067-Ab-2; GM-Tg-cang-IP2067-Ab-1/ GM-Tg-cang-IP2067-Ab-2;
GM-Tg-bovg-IP2067-Ab-1/ GM-Tg-bovg-IP2067-Ab-2; GM-Tg-equg-IP2067-Ab-1/ GM-Tg-equg-IP2067-Ab-2
Products Name TMEM237 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name TMEM237
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TMEM237 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.